<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03957902</url>
  </required_header>
  <id_info>
    <org_study_id>PI17/01109</org_study_id>
    <secondary_id>2018-002101-65</secondary_id>
    <nct_id>NCT03957902</nct_id>
  </id_info>
  <brief_title>Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer</brief_title>
  <official_title>Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Sanitaria Aragón</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>G. d'Annunzio University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clínico Universitario Lozano Blesa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigación Sanitaria Aragón</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acetylsalicylic acid (ASA) seems the ideal colorectal cancer (CRC) chemoprevention agent.
      Several ongoing trials are testing the effect of ASA as co-therapy in CRC. The mechanisms of
      action, the appropriate dose and the ideal target population are unknown. The investigators
      have demonstrated that doses of 100 mg of ASA induce direct and partial but persistent
      acetylation of the cyclooxygenase (COX) isoenzyme COX-1 in the normal colorectal mucosa. The
      primary objective is to perform a study of aspirin by using a proteomic assay for comparing
      platelet COX-1 and CRC mucosal COX-1 after different doses of ASA. Secondary objectives are:
      the measurement of prostaglandin E2 (PGE2) and phosphorylated S6 protein (p-S6) levels in CRC
      mucosa, the assessment of indirect biomarker of aspirin action (serum thromboxane B2 (TXB2)
      and urinary levels of 11-dehydro-TXB2 (TX-M)), the evaluation of systemic biomarkers of
      inflammatory/tumorigenic COX-2 by assessing urinary levels of major metabolite of PGE2
      (PGE-M). Methods: Phase II randomized clinical trial in 60 patients with newly diagnosed CRC
      in 3 groups of 20 patients receiving 100 or 300 mg/day, or 100 mg/12 hours of enteric-coated
      ASA for 3±1 weeks, prior to definitive treatment by surgery. Main outcome: Acetylation of
      COX-1 and COX-2. Eicosanoid levels in target organs. Expected results: Evidence for the
      current uncertainty about the mechanisms of action and the dose required to obtain the best
      chemopreventive effect with ASA in CRC. Confirm acetylation of COX as a key biomarker of
      efficacy with ASA.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of changes in acetylation levels of COX enzymes in platelets and non-neoplastic and neoplastic colonic tissues</measure>
    <time_frame>before the beginning of the treatment and 3 ± 1 weeks of acetylsalicylic acid treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of changes in prostaglandin E2 (PGE2) levels in colorectal mucosa depending on drug dosis</measure>
    <time_frame>before the beginning of the treatment and 3 ± 1 weeks of acetylsalicylic acid treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of changes in phosphorylated S6 protein (p-S6) levels in colorectal mucosa depending on drug dosis</measure>
    <time_frame>before the beginning of the treatment and 3 ± 1 weeks of acetylsalicylic acid treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of changes in thromboxane B2 (TxB2) levels in urine as indirect systemic biomarker depending on drug dosis</measure>
    <time_frame>before the beginning of the treatment and 3 ± 1 weeks of acetylsalicylic acid treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of changes in urinary metabolite 11-dehydro-TxB2 (TX-M) levels as indirect systemic biomarker depending on drug dosis</measure>
    <time_frame>before the beginning of the treatment and 3 ± 1 weeks of acetylsalicylic acid treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of changes in major urinary metabolite of PGE2 (PEG-M) levels depending on drug dosis</measure>
    <time_frame>before the beginning of the treatment and 3 ± 1 weeks of acetylsalicylic acid treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1 (100 mg/24h)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (300 mg/24h)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 (100 mg/12h)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid</intervention_name>
    <description>Different dosage effect over platelet COX enzymes, non- neoplastic and neoplastic colonic tissues used as biomarkers of clinical efficacy in CRC chemoprevention</description>
    <arm_group_label>Arm 1 (100 mg/24h)</arm_group_label>
    <arm_group_label>Arm 2 (300 mg/24h)</arm_group_label>
    <arm_group_label>Arm 3 (100 mg/12h)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥ 18 &lt; 80 years old

          -  recent diagnosis (&lt; 48h) of rectum or colon cancer, established by endoscopy and later
             confirmed by anatomo-pathologic study

          -  normal coagulation values and biochemical vales without clinically significant
             deviations that, at the discretion of the investigator, may interfere with the study
             procedures

        Exclusion Criteria:

          -  Allergy to ASA or to any other NSAID.

          -  Rectal cancer requiring neoadjuvant treatment within the two weeks following the
             beginning of ASA treatment.

          -  Previous use of ASA, NSAIDs, antiplatelet agents, corticosteroids or misoprostol
             within the 15 days prior to diagnosis and/or anticipation of need for treatment with
             any of these drugs during the study period. History of peptic ulcer disease or active
             peptic ulcer or any other gastrointestinal disease that may be considered a
             contraindication to the use of ASA, without the concomitant use of proton pump
             inhibitors.

          -  Diagnosis of bleeding disorders.

          -  Diagnosis of cancer (excluding non-melanoma skin cancer) within the previous 3 years.

          -  Conditions supposing serious comorbidity, excluding diabetes, and including
             respiratory, cardiac, hepatic and renal diseases.

          -  Active smoking.

          -  Pregnancy or breastfeeding.

          -  History of drug or alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ángel Lanas Arbeloa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Investigación Sanitaria Aragón</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ángel Lanas Arbeloa, MD</last_name>
    <phone>0034976765786</phone>
    <email>angel.lanas@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ángel Lanas Arbeloa, MD</last_name>
      <phone>0034976765786</phone>
      <email>angel.lanas@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 13, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Investigación Sanitaria Aragón</investigator_affiliation>
    <investigator_full_name>Ángel Lanas Arbeloa</investigator_full_name>
    <investigator_title>Head of Digestive Diseases Service</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

